What drove the sell-off in 2 ASX health care stocks in 2025

Core Viewpoint - The ASX health care sector faced significant challenges in 2025, with CSL Limited and Pro Medicus Limited experiencing substantial declines, leading to a 24% drop in the ASX health care index over the past year. This situation reflects a reset in valuation and investor expectations rather than a fundamental collapse in the companies' operations [2]. Group 1: CSL Limited - CSL's shares have decreased by over one-third in 2025 due to a downgrade in financial projections, a paused spin-off, and lower influenza vaccination rates in a volatile US market [3]. - Despite the downturn, CSL remains a global leader in plasma therapies and vaccines, with a strong portfolio and a robust R&D pipeline. The core business fundamentals are intact, but investor expectations have been reassessed, creating a potentially improved risk-reward scenario [3][12]. - The company is expected to benefit from a cost savings program, and investors are advised to monitor gross margin stabilization before making further commitments [3]. Group 2: Pro Medicus Limited - Pro Medicus has seen a sell-off not due to business failures but because its share price had surged excessively, trading at over 300 times forward earnings [8]. - The company boasts exceptional operating earnings margins exceeding 70% and is recognized for its critical enterprise imaging software used in leading hospitals, indicating strong economic fundamentals [8]. - With ongoing growth in US hospitals and advanced technology, Pro Medicus presents a potential opportunity for investors to dollar cost average into a high-quality company [9]. Group 3: Market Sentiment and Future Outlook - The market has not abandoned CSL and Pro Medicus; rather, it has recalibrated the price investors are willing to pay for their earnings, reflecting a reassessment of their valuations [12]. - Both companies maintain world-class intellectual property, high returns on capital, and strong customer relationships, suggesting that the risk-reward profile may have improved following the sell-off [12]. - These companies are recommended for consideration on watchlists for investors looking to gain exposure to the global health care sector's tailwinds [13].